U.S. markets closed

Silverback Therapeutics, Inc. (SBTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
51.34-1.46 (-2.77%)
At close: 4:00PM EST

51.34 0.00 (0.00%)
After hours: 4:00PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close52.80
Open52.75
Bid38.00 x 1100
Ask51.42 x 1300
Day's Range50.55 - 54.03
52 Week Range24.22 - 54.41
Volume176,245
Avg. Volume264,023
Market Cap1.786B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Silverback Therapeutics to Present at Upcoming Investor Conferences

      Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Laura Shawver, Ph.D., Silverback’s chief executive officer, will present at the following upcoming investor conferences:

    • SVB Leerink Bullish On Silverback Therapeutics, Sees Diverse Pipeline
      Benzinga

      SVB Leerink Bullish On Silverback Therapeutics, Sees Diverse Pipeline

      Silverback Therapeutics Inc (NASDAQ: SBTX) recently raised $277.7 million by selling 13.225 million shares in an initial public offering that were priced at $21 each.The Silverback Analyst: SVB Leerink analyst Daina Graybosch initiated coverage of Silverback Therapeutics with an Outperform rating and $40 price target.The Silverback Thesis: Silverback is a leader in the field of immune stimulator antibody conjugates, with a pipeline of ImmunoTAC conjugated TLR8 agonists for oncology and virology indications, Graybosch said in the initiation note.Clinical data from the dose escalation trial of HER2-targeting SBT6050 due in 2021 could provide proof-of-principle for Silverback's ImmunoTAC platform, the analyst said. Related Link: The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks If HER2 tumors prove a challenge, Silverback will quickly have data from SBT6290 in bladder cancer, she said. "Beyond oncology, Silverback's discovery ImmunoTAC programs in virology and fibrosis add risk-mitigating diversification and provide near-term partnership/out-licensing opportunities."SBTX Price Action: Silverback shares gained 1.37% in Tuesday's session, closing at $37. Related Link: The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Latest Ratings for SBTX DateFirmActionFromTo Dec 2020SVB LeerinkInitiates Coverage OnOutperform Dec 2020StifelInitiates Coverage OnBuy Dec 2020HC Wainwright & Co.Initiates Coverage OnBuy View More Analyst Ratings for SBTX View the Latest Analyst RatingsSee more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica * The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Benzinga

      Benzinga's Top Upgrades, Downgrades For December 29, 2020

      Upgrades * For Continental Resources Inc (NYSE:CLR), KeyBanc upgraded the previous rating of Sector Weight to Overweight. Continental Resources earned $0.16 in the third quarter, compared to $0.54 in the year-ago quarter. The current stock performance of Continental Resources shows a 52-week-high of $36.20 and a 52-week-low of $6.90. Moreover, at the end of the last trading period, the closing price was at $16.26. Downgrades * For Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), Raymond James downgraded the previous rating of Outperform to Market Perform. For the third quarter, Arcturus Therapeutics had an EPS of $0.92, compared to year-ago quarter EPS of $0.56. At the moment, the stock has a 52-week-high of $129.71 and a 52-week-low of $8.51. Arcturus Therapeutics closed at $92.42 at the end of the last trading period. * According to HC Wainwright & Co., the prior rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) was changed from Buy to Neutral. In the third quarter, Arcturus Therapeutics showed an EPS of $0.92, compared to $0.56 from the year-ago quarter. The current stock performance of Arcturus Therapeutics shows a 52-week-high of $129.71 and a 52-week-low of $8.51. Moreover, at the end of the last trading period, the closing price was at $92.42. * For Aprea Therapeutics Inc (NASDAQ:APRE), RBC Capital downgraded the previous rating of Outperform to Sector Perform. For the third quarter, Aprea Therapeutics had an EPS of $0.58, compared to year-ago quarter EPS of $5.29. At the moment, the stock has a 52-week-high of $53.11 and a 52-week-low of $5.35. Aprea Therapeutics closed at $5.50 at the end of the last trading period. * Baird downgraded the previous rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) from Outperform to Neutral. For the third quarter, Arcturus Therapeutics had an EPS of $0.92, compared to year-ago quarter EPS of $0.56. At the moment, the stock has a 52-week-high of $129.71 and a 52-week-low of $8.51. Arcturus Therapeutics closed at $92.42 at the end of the last trading period. Initiations * Daiwa Capital initiated coverage on Splunk Inc (NASDAQ:SPLK) with a Neutral rating. In the third quarter, Splunk showed an EPS of $0.07, compared to $0.58 from the year-ago quarter. The stock has a 52-week-high of $225.89 and a 52-week-low of $93.92. At the end of the last trading period, Splunk closed at $175.55. * Morgan Stanley initiated coverage on Sigilon Therapeutics Inc (NASDAQ:SGTX) with a Equal-Weight rating. The price target for Sigilon Therapeutics is set to $45.00. At the moment, the stock has a 52-week-high of $54.32 and a 52-week-low of $22.00. Sigilon Therapeutics closed at $39.80 at the end of the last trading period. * With a Equal-Weight rating, Morgan Stanley initiated coverage on Seer Inc (NASDAQ:SEER). The price target seems to have been set at $65.00 for Seer. At the moment, the stock has a 52-week-high of $86.13 and a 52-week-low of $44.00. Seer closed at $64.40 at the end of the last trading period. * SVB Leerink initiated coverage on Silverback Therapeutics Inc (NASDAQ:SBTX) with an Outperform rating. At the moment, the stock has a 52-week-high of $36.70 and a 52-week-low of $24.22. Silverback Therapeutics closed at $36.50 at the end of the last trading period. * With a Buy rating, Stifel initiated coverage on Silverback Therapeutics Inc (NASDAQ:SBTX). The price target seems to have been set at $58.00 for Silverback Therapeutics. At the moment, the stock has a 52-week-high of $36.70 and a 52-week-low of $24.22. Silverback Therapeutics closed at $36.50 at the end of the last trading period. * Evercore ISI Group initiated coverage on BeyondSpring Inc (NASDAQ:BYSI) with an Outperform rating. The price target for BeyondSpring is set to $30.00. In the third quarter, BeyondSpring showed an EPS of $0.48, compared to $0.37 from the year-ago quarter. The current stock performance of BeyondSpring shows a 52-week-high of $21.50 and a 52-week-low of $9.38. Moreover, at the end of the last trading period, the closing price was at $10.96. * Jefferies initiated coverage on Sigilon Therapeutics Inc (NASDAQ:SGTX) with a Buy rating. The price target for Sigilon Therapeutics is set to $60.00. The current stock performance of Sigilon Therapeutics shows a 52-week-high of $54.32 and a 52-week-low of $22.00. Moreover, at the end of the last trading period, the closing price was at $39.80. * With an Overweight rating, JP Morgan initiated coverage on Seer Inc (NASDAQ:SEER). The price target seems to have been set at $75.00 for Seer. The stock has a 52-week-high of $86.13 and a 52-week-low of $44.00. At the end of the last trading period, Seer closed at $64.40. * For Seer Inc (NASDAQ:SEER), Cowen & Co. initiated coverage, by setting the current rating at Outperform. At the moment, the stock has a 52-week-high of $86.13 and a 52-week-low of $44.00. Seer closed at $64.40 at the end of the last trading period. * For Caesarstone Ltd (NASDAQ:CSTE), Benchmark initiated coverage, by setting the current rating at Buy. In the third quarter, Caesarstone showed an EPS of $0.41, compared to $0.29 from the year-ago quarter. At the moment, the stock has a 52-week-high of $15.86 and a 52-week-low of $7.65. Caesarstone closed at $10.80 at the end of the last trading period. * Benchmark initiated coverage on Porch Group Inc (NASDAQ:PRCH) with a Buy rating. The price target for Porch Group is set to $24.00. At the moment, the stock has a 52-week-high of $17.31 and a 52-week-low of $14.30. Porch Group closed at $14.71 at the end of the last trading period. * HC Wainwright & Co. initiated coverage on Tenax Therapeutics Inc (NASDAQ:TENX) with a Buy rating. The price target for Tenax Therapeutics is set to $5.00. In the third quarter, Tenax Therapeutics showed an EPS of $0.18, compared to $0.33 from the year-ago quarter. The stock has a 52-week-high of $2.68 and a 52-week-low of $0.25. At the end of the last trading period, Tenax Therapeutics closed at $1.07. * With a Buy rating, HC Wainwright & Co. initiated coverage on Silverback Therapeutics Inc (NASDAQ:SBTX). The price target seems to have been set at $44.00 for Silverback Therapeutics. The stock has a 52-week-high of $36.70 and a 52-week-low of $24.22. At the end of the last trading period, Silverback Therapeutics closed at $36.50.See more from Benzinga * Click here for options trades from Benzinga * Why Is It Moving? Analyzing The Upward Movement in BeyondSpring's Stock Today * Why Tenax Therapeutics's Stock is Trading Higher Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.